Fig. 2
From: Hematopoietic differentiation persists in human iPSCs defective in de novo DNA methylation
Characterization of iPSC-derived mesenchymal stromal cells. a Representative phase contrast images of iPSC-derived mesenchymal stromal cells (iMSCs) at day 35 for wildtype (WT) and knockout lines. Scale bar = 250 μm. b Flow cytometric analysis of surface markers of iMSCs at day 35. Significance was estimated by 2-way ANOVA with Tukey’s post hoc test; n = 10 for WT, n = 3 for exon 2 (exon 2−/− and exon 2+/−), n = 4 for exon 19, and n = 3 for exon 23 (*P < 0.05; **P < 0.01, ***P < 0.001, ****P < 0.0001; mean ± SD). c Scatter plots of DNAm levels (β-values) for all measured CpG sites (grey) in iMSCs derived from homozygous knockout lines for exon 2 (n = 1), exon 19 (n = 2), or exon 23 (n = 2), in comparison to corresponding WT lines. CpGs with more than 50% hyper- (red) and hypomethylation (blue) are indicated. Darker blue and red spots represent promoter-associated CpGs